Efficacy and safety of PD-1/PD-L1 inhibitors in different types of metastatic breast cancer: a systematic review and network meta-analysis
Many studies have been conducted to evaluate the effectiveness and safety of immune checkpoint inhibitors in metastatic breast cancer, but the results were not conclusive. The present network meta-analysis aimed to assess the effectiveness and safety of PD-1/PD-L1 inhibitors in different types of metastatic breast cancer. PubMed, Scopus, Web of Science, The Cochrane Library and ClinicalTrials.gov were searched. The primary outcomes were progression-free survival (PFS) and overall survival (OS). Safety was considered as secondary outcomes. Cochrane Risk-Of-Bias (RoB2) was used for the quality assessment of relevant articles. Random effect model was used for meta-analysis in the clinically relevant subgroups ( e.g., PD-L1/PD-1±, previously untreated/ refractory, and triple negative/hormone positive). In this network meta-analysis, 9 studies ( n =3785) were included. Our results revealed that in triple negative breast cancer patients, only durvalumab was associated with statistically significant improved OS (HR=0.49, 95%CrI=[0.30,0.80]) and atezolizumab + chemotherapy improved significantly PFS (HR=0.70,95%CrI=[0.38,0.92]). In PD-L1 positive subgroup, only atezolizumab + chemotherapy significantly improved PFS (HR=0.68,95%CrI=[0.42,0.99]) and OS (HR=0.63,95%CrI=[0.35,0.92]) compared with chemotherapy. In previously untreated subjects, only atezolizumab + chemotherapy significantly improved PFS (HR= 0.70, 95% CrI= [0.37, 0.91]) compared with chemotherapy. No significant difference was observed in adverse events of the comparisons while pembrolizumab + chemotherapy had more probability to cause adverse events when compared with chemotherapy. PD-1/PD-L1 inhibitors can more significantly improve PFS in the PD-L1 positive, previously untreated and metastatic triple negative breast cancer patients. However, more high-qualified trials must be still conducted to provide more definitive result for clinical practice.
Authors
- Erfan Sadeghi (ORCID: https://orcid.org/0000-0002-3873-8006)
- Mehran Beyki
- Vajihe Akbari (ORCID: https://orcid.org/0000-0003-0754-1486)
- Reza Amiri Khosroshahi (ORCID: https://orcid.org/0009-0004-6082-1756)
- Azadeh Moghaddas (ORCID: https://orcid.org/0000-0003-0412-6172)
- Shakiba Fathzadeh
Institutions
- Isfahan University of Medical Sciences (IR)
- Shiraz University of Medical Sciences (IR)
- Shahid Sadoughi University of Medical Sciences and Health Services (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- European journal of medical research
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1186/s40001-026-05405-6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Isfahan University of Medical Sciences